Cite this: Finally, some good news about CCR5 antagonists - Medscape - Mar 31, 2006. Commenting is limited to medical professionals. To comment please Log-in.

After the chemokine receptors CCR5 and CXCR4 were found to be the major HIV-1 coreceptors together with the primary receptor CD4, numerous efforts were made to test whether chemokines, chemokine ...

Additionally, he continues, “Our nanotechnology platform will be able to co-transport our anti-CCR5 antagonist with other therapeutics such as anti-amyloid antibodies with different and ...

VANCOUVER, Washington, July 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the ...

CytoDyn (OTCQB:CYDY) said on Tuesday that new data supports a new way its lead drug, leronlimab, a CCR5 antagonist, may help treat solid tumors by increasing levels of PD-L1.

Selzentry, Pfizer said, is the first in a new class of oral HIV medicines in more than 10 years. So-called CCR5 antagonists are designed to stop the virus outside the surface of cells before it ...